Related Experiment Video
Updated: Oct 30, 2025
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Cytogenetics of Pediatric Acute Myeloid Leukemia: A Review of the Current Knowledge
Julie Quessada1,2, Wendy Cuccuini3,4, Paul Saultier5,6
1Hematological Cytogenetics Laboratory, Timone Children's Hospital, Assistance Publique-Hôpitaux de Marseille (APHM), Faculté de Médecine, Aix Marseille University, 13005 Marseille, France.
Insights
Cytogenetic abnormalities are key for diagnosing pediatric acute myeloid leukemia (AML) and guiding risk-adapted therapy. This review details chromosomal changes, their impact on prognosis, and diagnostic challenges in pediatric AML.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Pediatric acute myeloid leukemia (AML) is a complex disease with significant heterogeneity.
- Despite improved outcomes, survival rates are around 70% and relapse rates remain high at 30%.
Purpose of the Study:
- To provide an updated review of cytogenetics in pediatric AML.
- To describe WHO-classified entities, new subgroups, and germline mutations with therapeutic implications.
Main Methods:
- Review of current WHO classification of AML.
- Analysis of chromosomal abnormalities, their frequency by age and AML subtype.
- Focus on de novo AML and cytogenetic diagnosis.
Main Results:
- Cytogenetics is crucial for AML diagnosis and prognosis.
- Specific chromosomal abnormalities correlate with risk-adapted therapy indications.
- New subgroups and germline mutations are identified with therapeutic relevance.
Conclusions:
- Understanding cytogenetic abnormalities is essential for optimizing pediatric AML treatment.
- Current diagnostic approaches and recommendations are highlighted.
- Further research into novel genetic subgroups may improve patient outcomes.
Abstract:
Pediatric acute myeloid leukemia is a rare and heterogeneous disease in relation to morphology, immunophenotyping, germline and somatic cytogenetic and genetic abnormalities. Over recent decades, outcomes have greatly improved, although survival rates remain around 70% and the relapse rate is high, at around 30%. Cytogenetics is an important factor for diagnosis and indication of prognosis. The main cytogenetic abnormalities are referenced in the current WHO classification of acute myeloid leukemia, where there is an indication for risk-adapted therapy. The aim of this article is to provide an updated review of cytogenetics in pediatric AML, describing well-known WHO entities, as well as new subgroups and germline mutations with therapeutic implications. We describe the main chromosomal abnormalities, their frequency according to age and AML subtypes, and their prognostic relevance within current therapeutic protocols. We focus on de novo AML and on cytogenetic diagnosis, including the practical difficulties encountered, based on the most recent hematological and cytogenetic recommendations.
